RedHill Biopharma (RDHL) Return on Capital Employed (2014 - 2023)
RedHill Biopharma (RDHL) posted quarterly Return on Capital Employed of 234.47% for Q2 2023, up 876690.0% year-over-year from N/an in Q2 2022, and down 315.75% quarter-over-quarter from 108.68% in Q4 2022.
RedHill Biopharma (RDHL) Return on Capital Employed (2014 - 2023) Analysis & Trends
RedHill Biopharma (RDHL) has reported Return on Capital Employed for 10 consecutive years, with 234.47% the latest figure, recorded in Q2 2023.
- In Q2 2023, Return on Capital Employed rose 876690.0% year-over-year to 234.47%; the TTM figure through Jun 2023 stood at 234.47% (up 876690.0% YoY), while the FY2025 annual figure was 321.15%, down 70702.0% from the prior year.
- Return on Capital Employed fell to 234.47% in Q2 2023 per RDHL's latest filing, from 108.68% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 108.68% in Q4 2022 and bottomed at 9001.37% in Q2 2022.
- Historically, Return on Capital Employed has averaged 982.89% across 5 years, with a median of 58.17% in 2021.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 905954 bps — and 2023, when it jumped 876690 bps.
- RedHill Biopharma's Return on Capital Employed stood at 92.79% in 2019, then plunged by 32 bps to 62.82% in 2020, then tumbled by 226 bps to 79.32% in 2021, then jumped by 237 bps to 108.68% in 2022, then sank by 316 bps to 234.47% in 2023.
- Business Quant data shows RDHL's Return on Capital Employed at 234.47% in Q2 2023, 108.68% in Q4 2022, and 9001.37% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -234.47% |
| Dec 31, 2022 | 108.68% |
| Jun 30, 2022 | -9,001.37% |
| Dec 31, 2021 | -79.32% |
| Jun 30, 2021 | 58.17% |
| Dec 31, 2020 | 62.82% |
| Jun 30, 2020 | 42.94% |
| Dec 31, 2019 | 92.79% |
| Jun 30, 2019 | 103.79% |
| Dec 31, 2018 | 82.78% |
| Jun 30, 2018 | 148.50% |
| Mar 31, 2018 | 123.01% |
| Dec 31, 2017 | 123.77% |
| Dec 31, 2016 | 54.36% |
| Mar 31, 2015 | 63.20% |
| Dec 31, 2014 | 57.72% |